CAR (chimeric antigen receptor) T-cell illustration.

Cell-Easy Signs Groundbreaking Manufacturing Contract, Paving the Way for Local Hospitals to Offer Next-Generation CAR-T Therapy.

Cell-Easy Signs Groundbreaking Manufacturing Contract, Paving the Way for Local Hospitals to Offer Next-Generation CAR-T Therapy Toulouse, France, march 26, 2024 –  This agreement with a pioneer European C&G company will soon enable the initiation of new clinical trials in South of France based on innovative CAR-T cell treatments  

Cell-Easy and Toulouse University Hospital obtain IMPD approval for first-in-human clinical trial in systemic sclerosis, using promising allogeneic approach

EU regulatory approval to administer Adipose-derived mesenchymal Stem Cells (ASCs) in patients with ischemic digital ulcers marks key milestone for partners Toulouse, France, November 16, 2023 – Cell-Easy, a French Contract Development and Manufacturing Organization (CDMO) focused on advanced cell therapies, and the Toulouse University Hospital, today announce that they

Cell Easy appoints CDMO expert Dr. Sebastien Ribault as Independent Board Director, to accelerate its rapid growth.

  TOULOUSE, France _ April 10, 2023 Cell-Easy is a leading contract development and manufacturing organization (CDMO) with a strong foothold in Good Manufacturing Practice (GMP) manufacturing services for immune cells (T, NK cells) and adult stem cells (MSCs, iPSCs). Since 2020, the company keeps expanding into genetically modified cells